

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

1 **I. Organizational Structure**

2 The Coordinating Center (CC) for the Pediatric Eye Disease Investigator Group (PEDIG) is the
3 Jaeb Center for Health Research in Tampa. The organizational structure includes the office(s) of
4 the Network Chair(s) and the following: Executive Committee (EC), Operations Committee
5 (OC), Steering Committees, and the Data and Safety Monitoring Committee (DSMC). Each
6 major protocol is developed by a Protocol Development Committee and is then administered by
7 a Steering Committee.
8

9 **A. Coordinating Center**

10 The CC is responsible for the development and maintenance of the organization of PEDIG. For
11 each study, staff in the CC has the responsibility for overseeing the development of the protocol,
12 development of operational and analytical methodology, the conduct of each study according to
13 the protocol, and analysis of all data. The CC serves as an administrative resource for study
14 investigators. It is actively involved in facilitating IRB approval and yearly renewals. For many
15 studies, the CC will be responsible for maintaining direct contact with patients. The CC will
16 maintain both the private and public websites for PEDIG.
17

18 **B. Network Chair(s) and Vice-chair(s)**

19 **a. Network Chair(s)**

20 The Network Chair(s) work closely with the CC. The Network Chair(s) have overall scientific
21 responsibility for PEDIG. Since its inception, PEDIG has been led by either a single Chair or
22 Co-chairs.
23
24

25 Responsibilities of the Network Chair(s) include the following:

- 26 • Co-Chair the Executive Committee
- 27 • Attend weekly call with the Coordinating Center
- 28 • Attend weekly calls of the Operations Committee
- 29 • Lead the monthly investigator conference calls (each to conduct 2 of the 4 calls)
- 30 • Lead the full PEDIG Investigator meetings in February and July of each year
- 31 • Lead the PEDIG investigator meetings that take place at the annual meetings of the
32 American Academy of Optometry, the American Academy of Ophthalmology, and the
33 American Association for Pediatric Ophthalmology and Strabismus
- 34 • Supervise and provide daily support to protocol chairs across multiple simultaneous study
35 protocols (one Co-Chair will be assigned primarily to each active protocol)
- 36 • Provide direction for future study protocols
- 37 • Serve as ad-hoc members on each PEDIG Committee (Strabismus Steering Committee,
38 Amblyopia Steering Committee, multiple weekly Protocol Planning Committees,
39 multiple weekly Writing Committees) except for the Data Safety & Monitoring
40 Committee (DSMC)
- 41 • Attend the DSMC meetings as non-voting members
- 42 • Review ideas for future protocols and direct the prioritization of ideas for protocol
43 development
- 44 • Serve as principal media contact(s) and primary public communicator(s) regarding the
45 Network

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

- 46 • Oversee the development of assigned study protocols which entails working closely
47 (weekly or several-times-a-week conference calls) with the Coordinating Center and with
48 the protocol development chair(s)
- 49 • Oversee the development of all manuscripts, working closely with the Coordinating
50 Center and with the lead author (weekly or several-times-a-week conference calls)
- 51 • Work closely with the Coordinating Center to oversee both site monitoring and protocol
52 monitoring, and to develop and maintain quality assurance
- 53 • Conduct site visits as needed
- 54 • Communicate with site investigators as needed to resolve issues, encourage enrollment,
55 and discuss other protocol or site-related issues

57 **b. Conference Calls**

58 Network Chair(s) will have a weekly conference call with the CC.

59

60 **c. Process for Selection of Network Chair(s)**

61 A single network chair or two co-chairs may be appointed. In the instance of co-chairs, ideally
62 there would be one ophthalmologist and one optometrist, assuming strong candidates from each
63 discipline. Approximately 2 years before the end of the tenure of the Chair(s), a solicitation will
64 be made to PEDIG investigators to nominate individuals for the position of network chair or co-
65 chair (an individual may nominate himself or herself). A formal application and review process
66 will be followed and is summarized in a separate operational document. It is expected that the
67 individual(s) will be selected and ultimately approved by the National Eye Institute (NEI) 21
68 months before the end of the 5-year term of the preceding network Chair. The individual(s) will
69 join the Operations Committee (if not already a member of the Operations Committee) at this
70 time, so as to be able to serve on the Operations Committee prior to assuming the Chair position.

71

72 **d. Network Vice-chair(s)**

73 One to three Vice-chairs will be selected depending on network needs and budget. If possible,
74 vice-chairs will be selected so that the Operations Committee includes at least one optometrist,
75 one academic ophthalmologist, and one private practice ophthalmologist. The Vice-chair(s) will
76 be selected by the Executive Committee following a solicitation to PEDIG investigators. A
77 formal application and review process will be followed and is summarized in a separate
78 operational document.

79

80 The Vice-chair position has a 1-year term after which a Vice-chair may be invited by EC to serve
81 a second 1-year term. Funding for each Vice-chair will be provided based upon the anticipated
82 percent effort, and the CC will provide administrative support.

83

84 There will be an annual application process starting in late Summer each year and a review of
85 applicants by the EC in November to appoint Vice-chair/s for the following year.

86

87 Responsibilities of a Vice-chair include the following:

- 88 • Serve as a member of the Operations Committee with responsibilities listed for that
89 committee, including participation on weekly or bi-weekly one-hour OC conference calls
- 90 • Participate on the Executive Committee
- 91 • Provide leadership at PEDIG investigator meetings (shared with Network Chair(s))

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

92

93 **C. Executive Committee**

94 The Executive Committee consists of the following standing members: all members of the
95 Operations Committee (see Section D), an expert in childhood vision assessment, and a
96 representative of the NEI. The Committee also includes rotating positions filled by
97 ophthalmologists, optometrists, and a site coordinator, all appointed for 24-month terms. An
98 investigator or coordinator from a site on probation is not eligible for nomination to the
99 Executive Committee. If a site is put on probation, any investigators or coordinators serving on
100 the Executive Committee may be asked to resign.

101

102 The Executive Committee is chaired by the Network Chair(s). The committee has regularly
103 scheduled meetings and conference calls, and convenes any time an issue requires its attention.

104

105 The Executive Committee is responsible for formulating general PEDIG policies. Included in its
106 responsibilities are the following:

107

- Develop requirements for investigators to be members of PEDIG
- Review and approve new PEDIG sites and investigators for applications not meeting established PEDIG requirements for which the Operations Committee believes that special consideration should be given.
- Review site performance issues brought to it by the Operations Committee, including sites and/or site personnel for which probation or dismissal from the network is being considered.
- Select Network Chair(s) and Vice-Chairs
- Prioritize studies for protocol development
- Approve Protocol Chairs as recommended by the Operations Committee
- Approve Steering Committee Chairs as recommended by the Operations Committee
- Review and approve all protocols, including protocol budgets, and any budgetary increases larger than \$25,000 or greater than 20% of the study budget after approved. Any budgetary increases less than \$25,000 or less than 20% of the study budget are approved by the Operations Committee.
- Review and approve all ancillary studies that utilize network resources
- Enforce the PEDIG editorial policy
- Identify potential funding sources

125

126 **D. Operations Committee**

127 The Operations Committee oversees the day-to-day activities of the entire network.

128

129 **a. Membership**

130

Members of the Operations Committee will include the following:

131

- Network Chair(s)
- Most recent past Network Chair
- Network Vice-chairs
- CC staff: Director, Past Director, Executive Assistant
- Other ad hoc members as needed, appointed by the Operations Committee

132

133

134

135

136

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)
ORGANIZATIONAL STRUCTURE
April 27, 2018

137 **b. Responsibilities**

138 Responsibilities of the Operations Committee include:

- 139 1) Protocol development
- 140 • Selection of a Protocol Development Committee, if indicated, for each
 - 141 protocol to be developed
 - 142 • Proposal of a Protocol Development Chair for the protocol development
 - 143 phase to the Executive Committee.
 - 144 • Proposal of a Protocol Chair for the active phase of the protocol (who will
 - 145 often have been the Protocol Development Chair) to the Executive
 - 146 Committee.
- 147 2) Oversight of Active Protocols
- 148 • Selection of Steering Committee members
 - 149 • At least one investigator member of the Operations Committee will
 - 150 participate on each Steering Committee.
- 151 3) Manuscripts
- 152 • Prioritizing manuscripts to be written, including review of manuscript ideas
 - 153 submitted by investigators.
 - 154 • Selection of a writing committee for each manuscript.
- 155 4) Presentations/dissemination of study results
- 156 • Determine professional meetings at which study results should be
 - 157 presented, and develop general plans for publicizing PEDIG results.
 - 158 • At least one member of the OC will review and approve all posters,
 - 159 presentations, and slide sets prior to submission.
 - 160 • Developing plan for dissemination of study results as indicated, often with
 - 161 NEI input.
- 162 5) Budget
- 163 • Oversight of the Network budget
- 164 6) Develop and maintain a program of quality assurance across all studies
- 165 • Monitor the performance of participating sites
 - 166 • Identify sites with excessive protocol deviations and/or quality issues to be
 - 167 reviewed by the Executive Committee
- 168 7) Review and approval of new sites and investigators
- 169 8) Each member of the Operations Committee will participate on the Executive
- 170 Committee

171
172 **c. Conference Calls**

173 A weekly or bi-weekly conference call of the Operations Committee will be held. Face-
174 to-face meetings will be scheduled as required.
175

176 **E. Protocol Chairs and Protocol Development Committees**

177 Each protocol will have a designated Chair or co-Chairs. Each Chair will be proposed by the
178 Operations Committee and approved by the Executive Committee. The Protocol Development
179 Chair and the Protocol Chair will often be the same person, but the Executive Committee will
180 appoint the Protocol Chair.

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

181 The Protocol Development Chair and Protocol Chair will focus on scientific aspects of a
182 protocol. During protocol development, the Protocol Development Chair will work with CC
183 staff and with the designated Network Chair to develop the protocol.

184
185 During the conduct of the study, the Protocol Chair will respond to queries from clinical sites
186 regarding the protocol, and as needed, to propose necessary modifications to the protocol.
187 Quality control aspects will be the responsibility of the Operations Committee.

188
189 The Protocol Chair may conduct protocol review calls with the investigators at the
190 commencement of a protocol and at pivotal points in the conduct of the protocol (e.g., the first
191 time a patient at a site is to have a masked exam in a protocol).

192
193 In general, the Protocol Chair will chair the writing committee for the primary manuscript from
194 the study and provide the initial public presentation of main outcomes.

195
196 A Protocol Development Committee will be appointed for each protocol. This will include the
197 Protocol Development Chair, network chair(s), one or more other investigators, and, as needed,
198 one or more coordinators. Appointment of some committee members may require specific
199 subcontracts (to be approved by the Operations Committee) for technical expertise, outcome
200 measure development, and pilot testing of materials and methods.

201
202 The responsibilities of the Protocol Development Committee are:

- 203 • Development of the final protocol, informed consent form, data forms, study procedures,
204 and other study materials
- 205 • Development of requirements for coordinators, investigators, and any other required
206 personnel to be certified for the protocol
- 207 • Pilot testing of study forms and procedures prior to start of patient recruitment or use in
208 the study

209 **F. Steering Committees**

211 A Steering Committee oversees the day-to-day running of each protocol. One Steering
212 Committee may oversee multiple protocols.

213
214 Members of each Steering Committee are appointed by the Operations Committee, and will
215 include the Network Chair(s), some members of the Executive Committee, the Protocol Chairs,
216 and other investigators and site coordinators on a rotational basis (generally for an 18-month
217 term).

218
219 A Steering Committee convenes by conference call monthly and additionally as needed.

220
221 Whereas the Executive Committee is responsible for issues related to PEDIG in general, Steering
222 Committees are responsible for issues specific to particular protocols. Specific functions of a
223 Steering Committee include:

- 224 • Consider changes or modifications to the protocol as necessary or desirable
- 225 • Advise and assist the CC on operational matters pertaining to the protocols
- 226 • Review and approve abstracts and manuscripts for each protocol in collaboration with the EC

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)
ORGANIZATIONAL STRUCTURE
April 27, 2018

227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272

G. Writing Committees

The PEDIG Operations Committee is responsible for selecting a writing committee for each manuscript. The OC provides oversight of manuscript writing, and at least one network chair will serve on the writing committee for each manuscript.

In general, each manuscript writing committee will consist of:

- A lead author (or author/s if applicable); for primary manuscripts, this is usually the protocol chair(s)
- A lead Jaeb statistician (or statisticians, if applicable)
- A Network Chair to provide oversight
- Additional study group members (investigators and coordinators) nominated by the Operations Committee based upon level of recruitment into the study, participation on planning/steering committee, and/or particular expertise in the area of interest

With OC approval, the lead author or OC member may add or remove authors to or from the writing committee based upon level of contribution.

H. Data and Safety Monitoring Committee (DSMC)

The Data and Safety Monitoring Committee (DSMC) has the responsibility for reviewing the ethical conduct of a study and for monitoring the data for evidence of adverse or beneficial treatment effects. Results are not available to the participating investigators who are treating or examining patients until the DSMC recommends that this information be released. The DSMC is responsible for all major studies and is kept abreast of, but is not responsible for, unfunded data collections.

The members of the DSMC will be selected by the National Eye Institute, which will select one of the members to serve as the Chair. The committee will include individuals with expertise in clinical trials, biostatistics, and pediatric ophthalmology, as well as a layperson. The NEI Project Officer will be considered an ex-officio non-voting member.

Prior to the initiation of recruitment for a study, the DSMC reviews the study protocol, including the informed consent procedure and form. The DSMC periodically reviews the study progress (at least twice each year either at a meeting or a conference call). Both efficacy and safety are reviewed regularly. Decisions made by this committee relating to protection of patient rights and/or resulting from data analyses are forwarded to the NEI and then, if indicated, to the Steering Committee. The committee determines specific plans for evaluating adverse effects and efficacy, including stopping rules for each protocol.

A separate Standard Operating Procedures document contains more details about DSMC functions.

I. Clinical Sites

a. Sites

Institutional or private-practice based entities may participate in PEDIG as a clinical site

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

273 provided the site has at least one individual who meets criteria to be an investigator as
274 defined in section (b1) below.

275
276 One investigator at the site must be designated as the principal investigator who will be
277 responsible for PEDIG activities at the site. The responsibilities of a site PI are detailed in
278 section (b3) below.

279
280 A participating site must also have at least one individual who meets criteria to be
281 designated a primary site coordinator as defined in section (c) below.

282

283 **b. Investigators**

284 1) Investigator

285 Investigator status is open to all who meet the following qualifications:

- 286 • Pediatric ophthalmologists who have completed a pediatric ophthalmology
287 fellowship or have comparable clinical experience (as determined by the
288 Operations Committee) and whose practice is at least 40% pediatric eye care
289 and/or strabismus.
- 290 • Pediatric optometrists who have completed a pediatric optometry residency or
291 have comparable clinical experience (as determined by the Operations
292 Committee) and whose practice is at least 40% pediatric eye care and/or
293 strabismus.
- 294 • Other clinicians as required by a particular protocol as determined by the
295 Executive Committee.

296

297 Each investigator will be reviewed and approved by the Operations Committee and/or
298 the Executive Committee prior to joining PEDIG. Specific requirements may exist for
299 an investigator to participate in a particular protocol. A PEDIG investigator can elect
300 to participate in any or all studies for which he or she meets the certification
301 requirements. Investigators may be required to participate in at least one study to
302 maintain active membership.

303

304 2) Associate Investigator

305 An individual who works with a PEDIG investigator (with investigator status) and
306 who does not meet criteria for investigator can apply to be an associate investigator.

307 An associate investigator can participate in protocols under the supervision of an
308 investigator. An associate investigator cannot independently enroll patients, although
309 he/she can screen patients, obtain informed consent as determined by the IRB, perform
310 the examination that is used for enrollment, and perform follow-up exams. An
311 investigator with full investigator status (i.e., not an associate investigator), must
312 assume responsibility for verifying eligibility and ensuring that the associate
313 investigator follows the study protocol.

314

315 Associate investigators may petition the PEDIG Executive Committee to enroll
316 patients for one or more protocols or the Executive Committee may decide that any
317 Associate Investigator may enroll for a particular protocol.

318

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

319 A PEDIG site cannot be active with only associate investigator(s) except in
320 exceptional situations approved by the Executive Committee.

321
322 Specific requirements will exist for an associate investigator to participate in each
323 protocol. An associate investigator can elect to participate in any or all studies for
324 which he or she meets the certification requirements. Associate investigators may be
325 required to participate in at least one study to maintain active membership.

326
327 An associate investigator can apply for a change in status if he/she should meet the
328 criteria to become an investigator.

329
330 If an associate investigator does not meet the criteria to become a full investigator,
331 he/she can apply for full investigator status after two years of participation in PEDIG
332 after satisfying alternative criteria specified below.

- 333 • The associate investigator must submit to the Executive Committee a summary
334 of involvement in PEDIG studies
- 335 • He/she should also demonstrate a consistent and active role in several studies.

336
337 3) Responsibilities of PEDIG Principal Investigators

338 Each clinical site that is approved to participate in the Pediatric Eye Disease
339 Investigator Group (PEDIG) will have one individual designated as the Principal
340 Investigator (PI) of the site. The PI has ultimate responsibility for PEDIG activities at
341 that site.

342
343 Specific responsibilities of PIs of PEDIG clinical sites regarding research data
344 integrity include, but are not limited to, the following:

- 345 • To have a thorough understanding of the PEDIG policies, protocol designs, and
346 study methods.
- 347 • To ensure that local institutional requirements (if applicable) are satisfied and
348 that approvals and assurances are obtained annually.
- 349 • To ensure that the required PEDIG-certified staff, facilities, and equipment are
350 available to meet PEDIG responsibilities.
- 351 • To provide adequate support and guidance to site investigators, coordinators
352 and other staff so that the PEDIG studies can be conducted according to
353 protocol.
- 354 • To respond promptly to requests from the CC, the Network or Protocol Chair's
355 Office or the National Eye Institute.
- 356 • To correspond and maintain accessibility via email and phone with your
357 PEDIG protocol monitor and Vice-chair liaison to the Operations Committee
- 358 • To oversee local PEDIG documentation and records.
- 359 • To conduct periodic meetings of PEDIG personnel at his/her site(s).
- 360 • To cooperate with protocol monitors by working with the site coordinator to
361 make available PEDIG personnel, PEDIG records and protocol binders, clinic
362 charts for PEDIG study participants, and other necessary records needed for
363 on-site clinic monitoring.

PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG)

ORGANIZATIONAL STRUCTURE

April 27, 2018

- 364 • To notify the CC if any protocol adherence or data reporting problem is
365 discovered or suspected.
- 366 • To attend scheduled PEDIG meetings and conference calls, including those for
367 any PEDIG committees to which appointed.
- 368 • To review the site report card evaluating clinical site performance and to
369 discuss with the local PEDIG personnel any areas identified to be deficient.
370

371 **c. Coordinators**

372 The study coordinator plays a critical role in the conduct of PEDIG-sponsored studies in
373 ensuring the integrity of the research data. Together with the principal investigator, the
374 coordinator ensures that patients receive appropriate consent, subjects meet all eligibility
375 criteria, study protocols are followed correctly, study procedures are completed accurately,
376 and data is entered accurately on the PEDIG website. These responsibilities require detailed
377 and complete knowledge of each protocol and complete familiarity with the informed consent
378 process and data collection procedures.
379

380 All sites must have a designated study coordinator responsible for the aforementioned duties
381 as well as communication with the CC. Orthoptists, technicians, and administrative support
382 personnel may serve as study coordinators. There may be additional, institution-specific
383 requirements to serve in this role. Coordinators will be responsible for some elements of
384 testing consistent with their skills, completing forms, managing edits, and maintaining contact
385 with patients and the CC to facilitate their investigators' participation in studies. They are
386 recognized in the published list of study center personnel as Coordinators in PEDIG
387 publications. Ideally, a back-up coordinator should be available to fill in for the primary
388 coordinator in case of sickness or vacation. Investigators may act as study coordinators with
389 approval from the Operations Committee.
390

391 **d. Clinical Testers**

392 Orthoptists, technicians, optometrists, ophthalmologists, and administrative personnel may
393 serve as clinical testers after certification by the CC. There may be specific qualification
394 requirements for specific tests (e.g., only an ophthalmologist, optometrist, certified orthoptist,
395 or certified COMT may perform alignment testing.) Such requirements are determined by the
396 protocol development committee and approved by the Executive Committee as part of the
397 protocol approval process. Clinical testers are recognized in the published list of study center
398 personnel in PEDIG publications.